StudyFinder

A Randomized, Double-Blind, Multicenter, Placebo-Controlled Phase 3 Study with Open-Label Period to Evaluate the Efficacy and Safety of Inebilizumab in Adults with Myasthenia Gravis

Recruiting

This is a randomized, double-blind, placebo-controlled, parallel-group study with an optional open-label extension testing the safety and efficacy of inebilizumab in participants with Myasthenia Gravis.

I'm interested

This study is NOT accepting healthy volunteers

Myasthenia Gravis, Rare Diseases

Clinics and Surgery Center (CSC), Myasthenia Gravis

Emily Harper - harpe442@umn.edu
Georgios Manousakis
Phase III
STUDY00010270
NCT04524273
See this study on ClinicalTrials.gov

Back